Jianqing Zhu
38 Guangji Road
Hangzhou, 310022, China
Hangzhou, 310022, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study.
Journal: American journal of hematology
Published: April 21, 2026
Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial.
Journal: Journal of ovarian research
Published: February 10, 2026
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
Journal: CA: a cancer journal for clinicians
Published: September 15, 2025
Efficacy and Safety of Pamiparib Monotherapy in Recurrent Ovarian Cancer After Prior PARPi Exposure: A Prospective, Open-Label, Single-Arm, Phase II Study.
Journal: The journal of obstetrics and gynaecology research
Published: August 29, 2025
Evolution of Multivalent Aptamer Corona for High-Throughput Multiplexed Detection of Multiple Cancers.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: August 05, 2025
Optimal timing of primary debulking surgery in advanced ovarian cancer: insights from the TRUST trial.
Journal: Journal of gynecologic oncology
Published: August 04, 2025
Expression of membrane-bound Interleukin-15 sustains the growth and survival of CAR-NK cells.
Journal: International immunopharmacology
Published: May 13, 2025
Spatially resolved proteomics surveys the chemo-refractory proteins related to high-grade serous ovarian cancer.
Journal: Clinical and translational medicine
Published: March 30, 2025
A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer.
Journal: EClinicalMedicine
Published: March 05, 2025
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.
Journal: Med (New York, N.Y.)
Published: October 22, 2024
Multicenter study of ovarian cancer score for diagnosing ovarian cancer.
Journal: Gynecologic oncology
Published: October 20, 2024
Bimodal accurate H2O2 regulation to equalize tumor-associated macrophage repolarization and immunogenic tumor cell death elicitation.
Journal: Chemical science
Published: September 18, 2024
Last Updated: 09/26/2026